sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc through a Form 8.3 submission under the Irish Takeover Panel rules. On December 3, 2025, Vanguard reported holding 5,577,794 ordinary shares, representing a 5.73% stake in Avadel.
The filing reveals transactions involving US$0.01 ordinary shares, including a purchase of 132 shares at $21.36 each. Additionally, sales include 2,419 shares at $21.36 and 2,342 shares at $21.37.
No cash-settled or stock-settled derivatives activities were reported, and there were no indemnity or option arrangements in place relating to Avadel securities.
This disclosure is in accordance with the Irish Takeover Panel Act, 1997, reflecting transparency requirements for parties holding significant interests in relevant securities.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.